source
- Insmed's inhaled PAH therapy shows durable efficacy in 12-month extension, bolstering $6B sales outlookInsmed reported that its inhalable prostanoid candidate, treprostinil palmitil inhalation powder (TPIP), maintained functional and biomarker benefits through a 12‑month open‑label extension in pati…
- FDA says former officials' journal articles do not represent agency policy after lawmaker criticismActing FDA director Kyle Diamantas wrote to House Energy & Commerce ranking member Diana DeGette, stating that journal papers authored by former agency officials do not convey FDA policy or regulat…BioSpace · 1mo agoRegulatoryNegative